Carbocyclic oxetanocins lacking the C-3' methylene

Area of Science:

• Medicinal Chemistry
• Virology
• Organic Synthesis

Background:

• Aristeromycin, a carbocyclic adenosine analog, exhibits side effects potentially linked to its central methylene group.
• Modifications to nucleoside analogs can alter their biological activity and therapeutic profiles.

Purpose of the Study:

• To synthesize and evaluate carbocyclic oxetanocin derivatives lacking the 3"-methylene group.
• To assess the antiviral activity of these novel compounds against specific viruses, particularly herpes simplex virus type 1 (HSV-1) and varicella-zoster virus (VZV).

Main Methods:

• Synthesis of racemic derivatives of carbocyclic oxetanocin A, oxetanocin G, and 2-aminooxetanocin A, specifically designed to lack the 3"-methylene.
• Antiviral screening to determine the minimum inhibitory concentration (MIC) against various viruses, with a focus on HSV-1 and VZV.

Main Results:

• The synthesized compounds exhibited appreciable inhibitory effects only against herpes simplex virus type 1 (HSV-1) and varicella-zoster virus (VZV), with MICs ranging from 1 to 40 microg/mL.
• When directly compared to their parent compounds, oxetanocin A and oxetanocin G, the modified derivatives (4a and 4b) demonstrated significantly reduced antiviral potency against HSV-1.

Conclusions:

• Removing the 3"-methylene group from carbocyclic oxetanocin analogs diminishes their antiviral efficacy, particularly against HSV-1.
• The 3"-methylene group appears to be important for the antiviral activity of these carbocyclic nucleoside analogs.